Diflucan 150 mg is instantly identified by medical personnel as a medicine for fighting off fungal infections or those organisms that cause illnesses to humans which are fungal by nature. Diflucan 150 mg is very effective when it comes to treating a large variety of infections caused by fungi, especially those that are Candidal by type such as Candida infections of the mouth, bloodstream, throat, and vagina (the so-called vaginal yeast infections).
Diflucan 150 mg is also very effective in helping to prevent fungal infections from developing in individuals who have rather weakened or weak immune systems, most especially those who have undergone transplant procedures, premature infants, and those who have developed a condition called neutropenia (abnormally low number of neutrophils in the blood) as a result of their cancer chemotherapy treatments. Diflucan 150 mg mainly acts by interrupting the creation or synthesis of the cell membranes (or the outer covering) of the fungal cells.
Diflucan 150 mg is a very useful triazole antifungal drug which is very different from the earlier-made azole antifungals like ketoconazole. Triazole drugs, instead of an imidazole ring, contain a triazole ring in their molecular makeup. Drugs with imidazole rings are mainly effective as topicals (to be applied on the skin), while Diflucan 150 mg and other triazole antifungal drugs are very effective only when put inside the body.
The common clinical uses of Diflucan 150 mg include the following:
- Treatment of external infections caused by Candida: Candida of the throat, mouth, and vagina (yeast infection).
- Treatment of internal infections caused by Candida: Candida infections in those with otherwise completely healthy immune systems, including infections of the kidneys, joints or bloodstream.
- As a second go-to medication for treating cases of cryptococcal meningoencephalitis, which is a type of fungal infection that affects the central nervous system.
- Prevention of the occurrence of Candida infections in individuals with weakened or weak immune systems. Such individuals include those who have undergone transplant operations, premature babies, people with advanced HIV infections, and patients who have developed a degree of neutropenia after their cancer chemotherapy.